Dr. Finn on the Potential of CDK Inhibition

Richard S. Finn, MD
Published: Thursday, Feb 13, 2014

Richard S. Finn, MD, associate professor of medicine, Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine at UCLA, discusses the potential of CDK inhibition in breast cancer and other malignancies.

There has been a significant amount of preclinical data to suggest CDK inhibition may be important in various malignancies. As the idea to inhibit CDK moves into histologies outside of breast cancer, it will be crucial to identify other biomarkers.

In breast cancer, researchers and oncologists have been fortunate. Estrogen receptor (ER) testing is part of the standard of care and many biomarkers that identify CDK 4/6 dependence occur in ER-positive disease. By selecting by ER status, many biomarkers are ‘captured’ that represent an intact RB pathway.

In other cancers, researchers and oncologists need to select patients better to produce benefit.

Richard S. Finn, MD, associate professor of medicine, Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine at UCLA, discusses the potential of CDK inhibition in breast cancer and other malignancies.

There has been a significant amount of preclinical data to suggest CDK inhibition may be important in various malignancies. As the idea to inhibit CDK moves into histologies outside of breast cancer, it will be crucial to identify other biomarkers.

In breast cancer, researchers and oncologists have been fortunate. Estrogen receptor (ER) testing is part of the standard of care and many biomarkers that identify CDK 4/6 dependence occur in ER-positive disease. By selecting by ER status, many biomarkers are ‘captured’ that represent an intact RB pathway.

In other cancers, researchers and oncologists need to select patients better to produce benefit.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Community Practice Connections: Oncology Best Practice™ Targeting Cell Cycle Progression: The Latest Advances on CDK4/6 Inhibition in Metastatic Breast CancerOct 31, 20181.0
Publication Bottom Border
Border Publication
x